France
· Delayed Price · Currency is EUR Transgene Statistics
Total Valuation
Transgene has a market cap or net worth of EUR 149.15 million. The enterprise value is 150.78 million.
| Market Cap | 149.15M |
| Enterprise Value | 150.78M |
Important Dates
The next estimated earnings date is Tuesday, September 24, 2024.
| Earnings Date | Sep 24, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
Transgene has 131.99 million shares outstanding. The number of shares has increased by 42.59% in one year.
| Shares Outstanding | 131.99M |
| Shares Change (YoY) | +42.59% |
| Shares Change (QoQ) | -12.84% |
| Owned by Insiders (%) | 70.04% |
| Owned by Institutions (%) | 1.10% |
| Float | 34.71M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 14.39 |
| PB Ratio | 7.28 |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -6.75 |
| EV / Sales | 19.09 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -4.04 |
Financial Position
The company has a current ratio of 1.79, with a Debt / Equity ratio of 110.78.
| Current Ratio | 1.79 |
| Quick Ratio | 1.69 |
| Debt / Equity | 110.78 |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.46 |
| Interest Coverage | -178.64 |
Financial Efficiency
Return on equity (ROE) is -83.54% and return on invested capital (ROIC) is -44.52%.
| Return on Equity (ROE) | -83.54% |
| Return on Assets (ROA) | -33.60% |
| Return on Capital (ROIC) | -44.52% |
| Revenue Per Employee | 56,028 |
| Profits Per Employee | -158,355 |
| Employee Count | 141 |
| Asset Turnover | 0.14 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -35.43% in the last 52 weeks. The beta is 0.78, so Transgene's price volatility has been lower than the market average.
| Beta (5Y) | 0.78 |
| 52-Week Price Change | -35.43% |
| 50-Day Moving Average | 1.06 |
| 200-Day Moving Average | 1.22 |
| Relative Strength Index (RSI) | 62.69 |
| Average Volume (20 Days) | 27,470 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Transgene had revenue of EUR 7.90 million and -22.33 million in losses. Loss per share was -0.22.
| Revenue | 7.90M |
| Gross Profit | -21.69M |
| Operating Income | -30.01M |
| Pretax Income | -22.33M |
| Net Income | -22.33M |
| EBITDA | -28.44M |
| EBIT | -30.01M |
| Loss Per Share | -0.22 |
Balance Sheet
The company has 15.67 million in cash and 17.30 million in debt, giving a net cash position of -1.63 million or -0.01 per share.
| Cash & Cash Equivalents | 15.67M |
| Total Debt | 17.30M |
| Net Cash | -1.63M |
| Net Cash Per Share | -0.01 |
| Equity (Book Value) | 15.61M |
| Book Value Per Share | 0.16 |
| Working Capital | 7.94M |
Cash Flow
In the last 12 months, operating cash flow was -34.67 million and capital expenditures -2.67 million, giving a free cash flow of -37.34 million.
| Operating Cash Flow | -34.67M |
| Capital Expenditures | -2.67M |
| Free Cash Flow | -37.34M |
| FCF Per Share | -0.28 |
Margins
Gross margin is -274.53%, with operating and profit margins of -379.90% and -282.63%.
| Gross Margin | -274.53% |
| Operating Margin | -379.90% |
| Pretax Margin | -282.63% |
| Profit Margin | -282.63% |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | -472.63% |
Dividends & Yields
Transgene does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -42.59% |
| Shareholder Yield | -42.59% |
| Earnings Yield | -19.64% |
| FCF Yield | -25.03% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |